Intelligence · Patents
Patents expiring in 2035
Annual patent cliff calendar for 2035 — US pharmaceutical patents by expiration date.
- Patents
- 1,447
Quick answer
1,447 indexed pharmaceutical patents have expiration dates in 2035. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 9012434
Natural combination hormone replacement formulations and therapies
granted -
US 9012508
Administration of intravenous ibuprofen
granted -
US 9012498
Biodegradable lipids for the delivery of active agents
granted -
US 9012460
1-(2-phenoxymethylphenyl)piperazine compounds
granted -
US 9012496
Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
granted -
US 9012469
Crystalline naloxol-peg conjugate
granted -
US 9012641
Crystalline forms of Prasugrel salts
granted -
US 9012506
Cross-linked fatty acid-based biomaterials
granted -
US 9012473
Modulators of ATP-binding cassette transporters
granted -
US 9012624
Compositions and methods for inhibiting expression of a gene from the JC virus
granted -
US 9012485
Dual-acting imidazole antihypertensive agents
granted -
US 9012647
Nitroxide modified non-steroidal anti-inflammatory compounds and uses thereof in the treatment and prevention of diseases or disorders
granted -
US 9012618
Nucleic acids encoding modified Ebola virus glycoproteins with diminished cytotoxicity while retaining native antigenic structures
granted -
US 9012467
Compositions for intratumoral administration
granted -
US 9012447
5-HT3 receptor antagonists
granted -
US 9012223
Methods for enhancing genome stability and telomere elongation in embryonic stem cells
granted -
US 9011913
Use of functionalized magnetic nanoparticles in cancer detection and treatment
granted -
US 9011857
Methods of treating cancer by administering EMP2 antibodies
granted -
US 2015112285
Transdermal Therapeutic System For Administering Rivastigmine Or Derivatives Thereof
granted -
US 9017644
Methods of treating autoimmune disorders and/or inflammatory disorders
granted -
US 9017661
Cardiac repair by reprogramming of cardiac fibroblasts into cardiomyocytes
granted -
US 9017653
Nitric oxide-releasing compositions and methods
granted -
US 9017670
Anti-Tie2 antibodies and uses thereof
granted -
US 9018162
Methods for rapidly treating severe hypoglycemia
granted -
US 9017725
Topical drug delivery systems for ophthalmic use
granted -
US 9018216
Solid forms of (R)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof
granted -
US 9018227
Nicotinic acetylcholine receptor agonists
granted -
US 9017982
Non-wild-type organophosphorus acid anhydrolases for enzymatic decontamination
granted -
US 9018210
Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
granted -
US 9018238
Inhibitor of casein kinase 1δ and casein kinase 1ε
granted -
US 9018204
2,4-pyrimidinediamine compounds and their uses
granted -
US 9018236
Cyclodextrin-based microemulsions, and dermatological uses thereof
granted -
US 9018170
Reduced volume formulation of glatiramer acetate and methods of administration
granted -
US 9018251
Method for treating brain cancer or reducing temozolomide-resistance of brain cancer cells
granted -
US 9017743
Bacterial extract for digestive or urinary tract disorders and process for its preparation
granted -
US 9018374
Crystal of amide compound
granted -
US 9018371
Adenosine derivatives, method for the synthesis thereof, and the pharmaceutical compositions for the prevention and treatment of the inflammatory diseases containing the same as an active ingredient
granted -
US 9018380
Heterocyclic modulators of HIF activity for treatment of disease
granted -
US 9018356
Anti-ANGPTL3 antibodies and uses thereof
granted -
US 9018201
Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency
granted -
US 9018175
3,4,4a,10b-Tetrahydro-1H-thiopyrano-[44,3-c] isoquinoline derivatives
granted -
US 9017730
Compositions and uses of materials with high antimicrobial activity and low toxicity
granted -
US 9018244
Benzopyran compounds, compositions and uses thereof
granted -
US 9018367
Single stranded DNA aptamers binding NF-κB/RelA
granted -
IL 172160
Method for non-invasive quantification of perfusion in a tissue
granted -
US 9023809
Phenylalanine dipeptide derivatives, compositions and use thereof
granted -
US 9023322
Chewing gum compositions comprising cannabinoids
granted -
US 9023371
Drug releasing coatings for medical devices
granted
Frequently asked questions
How many pharma patents expire in 2035?
1,447 published patents in our USPTO index have expiration dates falling in calendar year 2035.